Latest Revenue Forecast News

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Weebit Nano has lifted its FY 2026 revenue forecast by over 12%, citing growth in customer projects ahead of its full-year results.

Advance ZincTek expects a 13% increase in unaudited profit before tax for FY26, driven by a 12.65% rise in sales revenue amid growing global enquiries.

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.

Bravura Solutions maintains FY26 revenue guidance while raising cash EBITDA expectations to $77 million, driven by robust project services demand and disciplined cost management.

Southern Palladium’s latest DFS metallurgical tests reveal a dramatic jump in chromite recovery to 85.6%, alongside improved platinum group metal grades and recoveries, potentially reshaping project economics.

Rubicon Water anticipates FY26 revenue between A$60 million and A$62 million, down from FY25’s A$69 million due to postponed major contract awards. Despite this, the company secured more contracts in H2 and grew its major project pipeline, setting the stage for potential FY27 growth.

Stakk Ltd anticipates its first operating profit in FY2026, driven by a surge in recurring revenue and major contract wins, with FY2027 revenue projected at $21.8 million based on existing agreements.

General Capital Limited posted record revenue growth of 18% to $26.76 million for FY26, driven by a 63% jump in loan receivables and a 34% rise in term deposits. The group declared a final dividend, reflecting confidence amid economic uncertainty and a positive credit rating upgrade for its finance subsidiary.

Austco Healthcare expects FY26 revenue between A$90 million and A$95 million, driven by strong sales and a significant US rollout. Net profit after tax is forecast to jump over 50%, supported by operational growth and a one-off benefit.

ParagonCare anticipates recovering up to 32.5% of its exposure to the insolvent Infinity Retail Pharmacy Group, while maintaining a steady FY26 earnings outlook amid cost pressures.

MaxiPARTS has seen activity levels dip due to the Middle East conflict but expects to maintain profit margins through cost controls and a resilient Förch Australia segment.